Evidence map›Paper›PMID 39564551›Full record

ArticleCase reports in oncology

Simultaneous Urothelial Carcinoma in the Upper Urinary Tract and Contralateral Renal Cell Carcinoma: A Case Report.

Keisuke Ishikawa, Masayoshi Nagata, Miki Tomari, Osamu Mito, Hisashi Hirano, Fumitaka Shimizu, Shuji Isotani, Hisamitsu Ide, Shigeo Horie

Abstract readCase Reports
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keisuke IshikawaDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Masayoshi NagataDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Miki TomariDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Osamu MitoDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hisashi HiranoDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Fumitaka ShimizuDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shuji IsotaniDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hisamitsu IdeDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shigeo HorieDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Although urological surgeons often diagnose cases of simultaneous double cancers of the urinary tract in our clinical practice, few reports have shown that treatment strategies achieve both anticancer effects and preservation of renal function for simultaneous contralateral renal cell carcinoma and urothelial carcinoma. Although there are many options for the treatment of renal cancer, such as immunotherapy and - drugs, and many surgical procedures, such as laparoscopic surgery and robot-assisted surgery, no treatment strategy has been established for double cancer of the bilateral urinary tracts. We encountered a case in which contralateral renal surgery was performed under a precise preoperative plan; as a result, the introduction of dialysis could be avoided, and the anticancer effect could be maintained. Case Presentation: A 73-year-old man was diagnosed with contralateral left renal cell carcinoma and right ureteral cancer. Initially, the patient underwent laparoscopic radical nephroureterectomy for right ureteral urothelial carcinoma. Subsequently, robot-assisted laparoscopic partial nephrectomy for left renal cell carcinoma was performed after treatment with the molecular-targeted agent, pazopanib. Even after partial nephrectomy, renal function was maintained, and dialysis was avoided. Conclusion: In cases of simultaneous renal cell carcinoma and contralateral ureteral cancer, it is possible to preserve both anticancer effects and renal function using careful treatment strategies.

Indexed as

ContralateralMolecular-targeted drugRenal cell carcinomaSimultaneousUrothelial carcinoma

Identifiers

PMID39564551
PMCPMC11575923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.